If access disappears after 2027, patients will likely stop therapy, regain weight, and end up back where they started
The starting dose matters enormously for tolerability
Because research is limited, side-effect information is not as strong as it is for FDA-approved medications
Of note, leveraging the two conserved segments (residues 49, 11, 14, 15, 18, 22 and 25), retatrutide and peptide 20 present a distinct design strategy, developed from the GIP and GCG backbones, respectively, to allow simultaneous agonism at the three pivotal receptors 1,13
It is a synthetic form of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1) that helps blood sugar regulation [1]
This dual-action approach may offer more significant weight loss and better overall blood sugar control than semaglutide in some patients